Dr Reddy’s terminates Armis Biopharma’s licence for its antibacterial product

As a result of the termination, the Indian drug maker has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward


Bengaluru: Termination of the license granted to Armis Biopharma for its investigational antibacterial product, DFA-02 by Dr Reddy’s Laboratories, has resulted in the regaining of worldwide rights by the company over the product.

DFA-02 is a combination, broad spectrum antibacterial product that has been studied in several phase 1 and 2 clinical studies, and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSls.

Dr Reddy’s is now currently evaluating its options to take the programme forward. In a separate regulatory filing, the company announced the closure of the sale of its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma Inc.

Neopharma Inc is a wholly-owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.

“This sale is in line with our stated priority to streamline and optimise our global cost structures and help us focus on other business priorities to drive growth,” Dr Reddy’s Labs Chief Operating Officer Erez Israeli said.